News report: the FDA's Wellcovorin file has ended as a withdrawal notice, not an autism-treatment rollout

A documentary image of the FDA campus fits this story because the live issue sits in the agency record itself: a September promise, a March approval for an ultrarare indication, and an April 10 sponsor-requested withdrawal notice that closed the Wellcovorin marketing path.[5][6]

As of 2026-04-11 23:06 UTC, the useful way to read the FDA's Wellcovorin file is no longer as a coming autism-treatment launch. It is an April 10 withdrawal notice. In the Federal Register, FDA said it is withdrawing approval of NDA 018342 for Wellcovorin because GSK told the agency the product was no longer marketed and asked that approval be withdrawn. FDA also said any inventory already on hand on April 10 may continue to be dispensed until depleted, expired, or otherwise violative.[5]

That outcome matters because the public story started in a very different register. On September 22, 2025, FDA said it had initiated approval of leucovorin calcium tablets to make treatment available for autism symptoms in patients with cerebral folate deficiency.[1] Two days later, the Federal Register published notice that the agency had reapproved the previously withdrawn application on the basis of new data, including literature on genetically confirmed FOLR1-linked cerebral folate deficiency.[2] By March 10, 2026, FDA's formal approval language was narrower: expanded use for adult and pediatric patients with cerebral folate deficiency who have a confirmed folate receptor 1 gene variant.[3] AP reported the same day that senior FDA officials said the strongest evidence supported only that ultrarare genetic condition, not autism broadly.[4]

Image context: the cover shows the path to an FDA main entrance on the White Oak campus in Silver Spring, Maryland. It fits because this story lives almost entirely inside the agency paper trail: a September promise, a March approval for an ultrarare indication, and an April 10 sponsor-requested withdrawal notice.[5][6]

Fact file

September 22, 2025: FDA said it had initiated approval of leucovorin calcium tablets to make treatment available for autism symptoms in patients with cerebral folate deficiency.[1]
September 24, 2025: the Federal Register published notice that FDA had approved the previously withdrawn Wellcovorin NDA on the basis of new data.[2]
March 10, 2026: FDA approved expanded use of Wellcovorin for cerebral folate deficiency in adults and children with a confirmed FOLR1 variant.[3]
March 10, 2026: AP reported FDA officials had narrowed the review to the strongest evidence and said the condition affects fewer than 1 in a million people in the United States.[4]
April 10, 2026: FDA withdrew approval at GSK's request because the product was no longer marketed; remaining inventory may still be dispensed until depleted or expired.[5]

What changed on April 10

The April 10 notice is narrow in one sense and consequential in another. It does not read like a safety failure or an FDA finding that the underlying evidence suddenly reversed. The agency says GSK notified FDA in writing that Wellcovorin was no longer marketed and requested withdrawal under 21 CFR 314.150(c); the company also waived the opportunity for a hearing.[5] That is a sponsor-requested market withdrawal. But it is still consequential because FDA withdrew approval of the entire NDA, including all amendments and supplements.[5]

That distinction is the central reporting point. In September and March, the file was publicly framed as an approval pathway. In April, the same file is no longer about whether the drug has a labeled lane on paper. It is about the fact that the sponsor asked to close that lane. The notice is explicit that Wellcovorin without an approved NDA cannot be introduced into interstate commerce after the withdrawal, even though already-held inventory may still be dispensed.[5]

Why the autism headline narrowed before the withdrawal

The file had already narrowed materially before the April notice arrived. FDA's September 22 press page yoked the story to autism symptoms and cerebral folate deficiency in the same announcement.[1] But the more formal September 24 Federal Register notice was built around something tighter. The agency said it had reviewed literature from 2009 through 2024 and found support for improvement of certain symptoms in adults and pediatric patients with cerebral folate deficiency tied to FOLR1 variants.[2] The notice also described autistic features as part of a heterogeneous symptom profile, not as a standalone approved indication.[2]

The March 10 approval completed that narrowing. FDA did not announce a broad approval for autism. It announced expanded use for patients with confirmed CFD-FOLR1.[3] AP's report made the boundary even plainer: senior FDA officials said their review had been narrowed to the strongest evidence, which supported only the ultrarare genetic condition, and they highlighted the retraction of one study that had been cited in support of autism use.[4] So by the time the April 10 withdrawal appeared, the file had already moved a long way from the public implication of a more general autism-treatment breakthrough.[1][3][4]

What the withdrawal does and does not mean

The April 10 notice does not establish that leucovorin suddenly stopped having any clinical relevance in the narrow FOLR1-linked condition. It also does not say FDA reversed the scientific reasoning spelled out in the September 2025 and March 2026 records. The source record supports a narrower conclusion: the marketed, sponsor-backed Wellcovorin NDA pathway that the agency publicized last fall is now withdrawn because GSK said the product was no longer marketed.[2][3][5]

That still changes the practical reading of the story. A drug file can be scientifically interesting, politically promoted, and formally approved, yet still fail to settle into durable commercial distribution. The April 10 notice turns this from a launch story into an availability and credibility story. For families, clinicians, and reporters, the safe description is no longer that FDA has an active approved rollout underway for an autism-adjacent treatment. The safer description is that FDA approved a very narrow rare-disease use on March 10, and one month later withdrew the product's NDA at the sponsor's request because the product was not being marketed.[3][5]

Decision impact by horizon

In the next 24 hours, anyone referencing the file should stop using last fall's broader autism framing without the later documents attached. The March 10 approval and the April 10 withdrawal need to travel together if the public record is going to be accurate.[1][3][5]

Over the next 7 days, the key question is whether FDA, HHS, or GSK explains the commercial gap between a March approval and an April sponsor-requested withdrawal. The existing record shows what happened procedurally, but not why a newly approved path failed to stay open even for a full quarter.[3][5]

Over the next 30 days, the larger significance is reputational. If no fuller explanation appears, this file will stand as a case where public autism messaging outran both the label boundary and the durability of the marketed product lane.[1][3][5]

The narrow and defensible reading is now clear. The Wellcovorin story did not end as a broad autism-treatment rollout. It ended, at least for now, as an April 10 Federal Register notice withdrawing approval of the product's NDA after GSK said the drug was no longer marketed.[5] The earlier paper trail still matters because it shows how the file moved from September 2025 autism-adjacent messaging to a March 10 approval for an ultrarare FOLR1-linked condition.[1][2][3][4] But as of April 11, 2026, the live regulatory fact is the withdrawal notice.

cronfeed.work